Introduction: Family planning services can bring a wide range of benefits to women, their families and society as a whole. Many women of reproductive age have little or incorrect information about family planning methods. Even when they know some methods of contraceptives, they don't know the availability or how to use them properly. The aim of this study is to find out the prevalence of contraception use among women visiting the outpatient department of gynaecology of a tertiary care centre.
Methods: A descriptive cross-sectional study was conducted among women visiting the gynaecological outpatient department from 10 April 2021 to 10 April 2022 after taking ethical approval from the Institutional review committee (Reference number: 2079/80-03). Women aged 18 to 49 years visiting during the study period were included and pregnant, postmenopausal and unmarried women were excluded from the study. Data was collected from one-to-one interviews. A convenience sampling method was used. Point estimate and 95% confidence interval were calculated.
Results: Out of 208 patients, 146 (70.19%) (63.97-76.41, 95% Confidence Interval) women were currently using contraceptives. Short-acting reversible contraception was used by 97 (66.44%) and long-acting reversible contraception was used by 23 (15.75%). A total of 21 (14.38%) women used permanent sterilisation. The most commonly used contraceptive device was Depo Provera, 43 (29.45%) followed by condoms, 29 (19.86%).
Conclusions: The prevalence of contraception use is lower than the other studies done in similar settings. Therefore, contraception promotion programs have to be encouraged to promote the efficient use of contraception.
Keywords: contraception; family planning; prevalence; women.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088992 | PMC |
| http://dx.doi.org/10.31729/jnma.7965 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parametric modeling of under-5 children survival among 30 African countries: Lognormal accelerated failure time gamma shared frailty model.
PLoS One
January 2025
Department of Environmental and Occupational Health and Safety, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
Background: Under-five mortality continues to be a serious public health concern in low-and middle-income countries, particularly in Africa. This study investigates the probability of under-five survival and its predictors of mortality in the African continent using a recent demographic health survey from 2014-2022.
Methods: This study utilized recent Demographic and Health Survey data from 30 African countries, encompassing 226,862 live births.
Long-acting reversible and permanent contraceptives utilization and its associated factors among married women who desire no more children in Ethiopia: A multilevel analysis.
PLoS One
January 2025
Department of General Midwifery, School of Midwifery, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Objective: This study aimed to investigate long-acting reversible and permanent contraceptives (LARPCs) utilization and its associated factors among married women who desire no more children in Ethiopia.
Methods: Secondary datasets from the 2016 Ethiopian Demographic and Health Survey was used for the study. A total weighted sample of 3,756 married or in union reproductive age women who desire no more children were included in the analysis.
Romosozumab Improves Tissue Thickness-Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes.
J Clin Endocrinol Metab
January 2025
The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Context: Trabecular bone score (TBS), a gray-level texture index derived from lumbar spine (LS) dual-energy x-ray absorptiometry (DXA) scans, is decreased in patients with diabetes and is associated with increased fracture risk, independent of areal bone mineral density (aBMD), but potentially influenced by abdominal fat tissue.
Objective: Evaluate effect of romosozumab (210 mg monthly) for 12 months followed by alendronate (70 mg weekly) for 24 months vs alendronate alone (70 mg weekly) for 36 months on LS aBMD and TBS in women with type 2 diabetes (T2D) enrolled in the ARCH study.
Methods: This post hoc analysis included women from ARCH who had T2D at baseline and LS DXA scans at baseline and ≥1 postbaseline visit (romosozumab-to-alendronate, n = 165; alendronate-to-alendronate, n = 195).
Hybrid remote and in-clinic maternal-fetal surveillance for women with gestational diabetes: A prospective pilot study.
Int J Gynaecol Obstet
January 2025
The Josef Buchmann Gynecology and Maternity Center, Sheba Medical Center, Tel Hashomer, Israel.
Objective: This study explores a hybrid approach to maternal-fetal care for gestational diabetes (GD), integrating virtual visits seamlessly with in-clinic assessments. We assessed the feasibility, time efficiency, patient satisfaction, and clinical outcomes to facilitate wider adoption of maternal-fetal telemedicine.
Methods: We conducted a 4-week prospective study involving 20 women with GD at ≥32 weeks of pregnancy, alternating between remote and in-clinic weekly visits.
Benefit Design and Access to Dental Care Among Seniors With Medicare Advantage Dental Benefits.
JAMA Health Forum
January 2025
Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, Massachusetts.
Importance: Although Medicare Advantage plans frequently offer dental benefits, enrollees report lower rates of dental care use and higher rates of unmet dental need compared with individuals with employer-sponsored benefits. It is unknown which attributes of Medicare Advantage dental plans are associated with enhanced dental care access.
Objective: To determine attributes of Medicare Advantage dental plans associated with higher rates of dental care use and lower rates of unmet dental need.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!